-
Featured
Mortality in COVID-19 Does Not Appear to Be Driven by Liver Failure
Massachusetts General Hospital researchers report that elevated liver function tests are common in COVID-19, but severe liver injury is rare, and no case of liver failure or dysfunction leading to death has been attributed directly to COVID-19.
-
Featured
Patients with Decompensated Cirrhosis Need Earlier End-of-Life Planning
Regardless of transplant candidacy, patients with decompensated cirrhosis spend a substantial portion of their last 90 days of life in the hospital, are likely to receive intensive interventions at the end of life and tend to be referred late, if at all, to palliative or hospice care.
-
Featured
Early Transplantation for Alcohol-associated Hepatitis Improves Survival
According to a mathematical model, offering liver transplantation with no minimum period of sobriety before surgery (i.e., early liver transplantation) for severe alcohol-associated hepatitis provides a fourfold increase in life expectancy compared with requiring a six-month period of sobriety before listing. having characteristics similar to patients in ACCELERATE-AH trial.
-
Physical Activity Reduces Chronic Liver Disease Mortality Risk
Massachusetts General Hospital researchers have demonstrated for the first time that exercise is an independent determinant of mortality from cirrhosis and its complications.
-
Epoxyeicosatrienoic Acid May Be a Biomarker for Nonalcoholic Steatohepatitis
Massachusetts General Hospital researchers have identified a non-invasive means to identify which patients with nonalcoholic fatty liver disease are at high risk of nonalcoholic steatohepatitis.
-
Case Series: Tocilizumab and Tofacitinib for Resolved Hepatitis B Infection
No episodes of hepatitis B virus (HBV) reactivation occurred with tocilizumab or tofacitinib treatment over three to four years of follow-up in a small case series of patients with resolved HBV from a U.S. health care system.
Liver contributors
-
Emily D. Bethea, MD
Associate Clinical Director of Liver Transplantation, Massachusetts General Hospital
-
Jagpreet Chhatwal, PhD
Associate Director, Institute for Technology Assessment, Assistant Professor, Harvard Medical School
Recent Article
COVID-19 Simulator Informs Local Policymaking: Q&A with Jagpreet Chhatwal, PhD
-
Kathleen E. Corey, MD, MPH
Director, Fatty Liver Clinic, Mass General Gastrointestinal Unit
Recent Article
Advanced Fibrosis Predicts Nonfatal CVD in NAFLD Patients
-
Raymond T. Chung, MD
Vice Chief, Gastrointestinal Division, Director of Hepatology and Liver Center, Medical Director, Liver Transplant Program
Recent Article
MGH Research Scholars Respond to COVID-19 -
Russell P. Goodman, MD, DPhil
Hepatologist, Division of Gastroenterology, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Imbalance of Electrons in the Liver May Be A Risk Factor for Many Common Diseases
Digestive Healthcare at Mass General
The Massachusetts General Hospital Digestive Healthcare Center is a collaborative practice of gastroenterologists, endoscopists, surgeons, radiologists, pathologists, hepatologists, oncologists and radiation oncologists dedicated to the prevention, diagnosis, treatment and management of digestive diseases.
